ArticleJournal of immunology (Baltimore, Md. : 1950)2021
CD40 Agonist Overcomes T Cell Exhaustion Induced by Chronic Myeloid Cell IL-27 Production in a Pancreatic Cancer Preclinical Model.
Article in Journal of immunology (Baltimore, Md. : 1950), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 31 citations in OpenAlex.
- Article
- Systemic immunosuppression limits NK cell therapy efficacy in pancreatic cancer.Molecular cancer · 2026Article
- CD40 Agonism in Pancreatic Ductal Adenocarcinoma: Expression, Biology, and Therapeutic Targeting.Cancers · 2026Review
- IL-15 complex enhances therapeutic efficacy of anti-PD-L1 in a T cell-dependent and NK cell-independent manner in a murine model of pancreatic ductal adenocarcinoma.Journal of immunology (Baltimore, Md. : 1950) · 2025Article
- Current status of chimeric antigen receptor T cell therapy and its exhaustion mechanism.Immunotherapy · 2025Review
- Combined Flt3L and CD40 agonism restores dendritic cell-driven T cell immunity in pancreatic cancer.Science immunology · 2025Article
- IL-15 Complex Enhances Agonistic Anti-CD40 + Anti-PDL1 by Correcting the T-bet to Tox Ratio in CD8+ T cells Infiltrating Pancreatic Ductal Adenocarcinoma.Cancer immunology research · 2025Article
- IL-12 family cytokines and autoimmune diseases: A potential therapeutic target?Journal of translational autoimmunity · 2025Review
- TNFR1 signaling promotes pancreatic tumor growth by limiting dendritic cell number and function.Cell reports. Medicine · 2024Article
- CD40 stimulation activates CD8+ T cells and controls HBV in CD4-depleted mice.JHEP reports : innovation in hepatology · 2024Article
- Current and future immunotherapeutic approaches in pancreatic cancer treatment.Journal of hematology & oncology · 2024Review
- New avenues for the treatment of immunotherapy-resistant pancreatic cancer.World journal of gastrointestinal oncology · 2024Review
- Tumor-specific CD4 T cells instruct monocyte fate in pancreatic ductal adenocarcinoma.Cell reports · 2023Article
- Cxcr3 constrains pancreatic cancer dissemination through instructing T cell fate.Cancer immunology, immunotherapy : CII · 2023Article
- Tumor Microenvironment in Pancreatic Cancer Pathogenesis and Therapeutic Resistance.Annual review of pathology · 2023Review
- Interrogating the CD27:CD70 axis in αCD40-dependent control of pancreatic adenocarcinoma.Frontiers in cell and developmental biology · 2023Article
- Distinct myeloid antigen-presenting cells dictate differential fates of tumor-specific CD8+ T cells in pancreatic cancer.JCI insight · 2022Article
- Identification of a tumor immune-inflammation signature predicting prognosis and immune status in breast cancer.Frontiers in oncology · 2022Article
- Therapeutic resistance in pancreatic ductal adenocarcinoma: Current challenges and future opportunities.World journal of gastroenterology · 2021Review
- Integrative Characterization of the Role of IL27 In Melanoma Using Bioinformatics Analysis.Frontiers in immunology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
Pancreatic cancer is a particularly lethal malignancy that resists immunotherapy. In this study, using a preclinical pancreatic cancer murine model, we demonstrate a progressive decrease in IFN-γ and granzyme B and a concomitant increase in Tox and IL-10 in intratumoral tumor-specific T cells. Intratumoral myeloid cells produced elevated IL-27, a cytokine that correlates with poor patient outcome. Abrogating IL-27 signaling significantly decreased intratumoral Tox
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.